These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 26847547)

  • 41. Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.
    Ahsan F; Oliveri F; Goud HK; Mehkari Z; Mohammed L; Javed M; Althwanay A; Rutkofsky IH
    Cureus; 2020 Sep; 12(9):e10446. PubMed ID: 33072455
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis.
    Cai J; Zhang XJ; Li H
    Hepatology; 2019 Sep; 70(3):1026-1037. PubMed ID: 30653691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
    Yahoo N; Dudek M; Knolle P; Heikenwälder M
    J Hepatol; 2023 Aug; 79(2):538-551. PubMed ID: 36893854
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
    Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
    Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CX3CR1-expressing inflammatory dendritic cells contribute to the progression of steatohepatitis.
    Sutti S; Locatelli I; Bruzzì S; Jindal A; Vacchiano M; Bozzola C; Albano E
    Clin Sci (Lond); 2015 Nov; 129(9):797-808. PubMed ID: 26253086
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
    Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
    Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis.
    Ni Y; Zhuge F; Nagashimada M; Ota T
    Nutrients; 2016 Jun; 8(7):. PubMed ID: 27347998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Role of Cholesterol in the Pathogenesis of NASH.
    Ioannou GN
    Trends Endocrinol Metab; 2016 Feb; 27(2):84-95. PubMed ID: 26703097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natural products that target macrophages in treating non-alcoholic steatohepatitis.
    Li CL; Zhou WJ; Ji G; Zhang L
    World J Gastroenterol; 2020 May; 26(18):2155-2165. PubMed ID: 32476782
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natural Killer Cells and Type 1 Innate Lymphoid Cells Are New Actors in Non-alcoholic Fatty Liver Disease.
    Luci C; Vieira E; Perchet T; Gual P; Golub R
    Front Immunol; 2019; 10():1192. PubMed ID: 31191550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The complex function of macrophages and their subpopulations in metabolic injury associated fatty liver disease.
    Subramanian P; Chavakis T
    J Physiol; 2023 Apr; 601(7):1159-1171. PubMed ID: 36825510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?
    Handa P; Vemulakonda A; Kowdley KV; Uribe M; Méndez-Sánchez N
    World J Gastroenterol; 2016 Aug; 22(31):6965-71. PubMed ID: 27610009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH).
    Jindal A; Bruzzì S; Sutti S; Locatelli I; Bozzola C; Paternostro C; Parola M; Albano E
    Exp Mol Pathol; 2015 Aug; 99(1):155-62. PubMed ID: 26112094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-Alcoholic Steatohepatitis: Clinical and Translational Research.
    Neuman MG; Voiculescu M; Nanau RM; Maor Y; Melzer E; Cohen LB; Opris M; Malnick S
    J Pharm Pharm Sci; 2016; 19(1):8-24. PubMed ID: 27096691
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice.
    Tosello-Trampont AC; Krueger P; Narayanan S; Landes SG; Leitinger N; Hahn YS
    Hepatology; 2016 Mar; 63(3):799-812. PubMed ID: 26662852
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical models of non-alcoholic fatty liver disease.
    Santhekadur PK; Kumar DP; Sanyal AJ
    J Hepatol; 2018 Feb; 68(2):230-237. PubMed ID: 29128391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased ratio of neutrophil elastase to α1-antitrypsin is closely associated with liver inflammation in patients with nonalcoholic steatohepatitis.
    Zang S; Ma X; Zhuang Z; Liu J; Bian D; Xun Y; Zhang Q; Zhao F; Yang W; Liu J; Luo Y; Liu Y; Ye B; Ye D; Shi J
    Clin Exp Pharmacol Physiol; 2016 Jan; 43(1):13-21. PubMed ID: 26444279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis.
    Thomsen KL; De Chiara F; Rombouts K; Vilstrup H; Andreola F; Mookerjee RP; Jalan R
    Med Hypotheses; 2018 Apr; 113():91-97. PubMed ID: 29523305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.